Neogenomics, Inc.: BofA Global Research raises price objective to $20 from $16
NEO•BofA Global Research raised its price objective for NeoGenomics to $20 from $16.
Related News
Tempus expands collaboration with Moderna, Merck on V940 melanoma vaccine support
TEM•
QEP declares quarterly cash dividend of $0.22 per share
QEPC•
Fuelcell Energy CFO Michael S. Bishop to end service October 6, 2026
FCEL•
Ultragenyx agrees to sell rare pediatric disease priority review voucher for $210 million
RARE•
London court quashes five more UK rate-rigging convictions
BCS•